OCU400
Phase 1/2- Indications
- Retinitis pigmentosa, Leber congenital amaurosis
Company intelligence / Profile preview
Biopeptek Pharmaceuticals LLC specializes in custom synthesis and cGMP manufacturing of synthetic peptides as active pharmaceutical ingredients (APIs) and sterile injectable formulations. The company acts as a contract development and manufacturing organization (CDMO/CMO) serving pharmaceutical and biotech clients globally from preclinical through commercial stages. It does not appear to have its own clinical-stage drug candidates but provides end-to-end support including process development, analytical services, regulatory documentation support for IND/NDA filings worldwide. Its expertise covers solid-phase/liquid-phase synthesis technologies with batch sizes up to multi-kilogram scale under FDA-compliant cGMP conditions. The company’s catalog includes numerous generic or reference-listed peptide APIs used in diverse therapeutic areas such as diabetes/metabolic disease hormones and cosmetic peptides.
4 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biopeptek Pharmaceuticals.